Citation Impact
Citing Papers
Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
2013
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
2014
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Molecular imaging in drug development
2008 Standout
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review
2005
Imaging beyond the proteome
2012 StandoutNobel
Guidelines for radioiodine therapy of differentiated thyroid cancer
2008
A view on drug resistance in cancer
2019 StandoutNature
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
2003 Standout
Thyroid cancer
2016 Standout
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
2013
Bisphenol A and human health: A review of the literature
2013 Standout
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
2010 Standout
Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
2007
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer
2011
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
2021
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
2011
Thyroid Gland Malignancies
2015
Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk
2011 Standout
Molecular imaging applications for immunology
2004
Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients
2007
PET Imaging of Soluble Yttrium-86-Labeled Carbon Nanotubes in Mice
2007
The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study
2007
Metabolic Labeling of Glycans with Azido Sugars for Visualization and Glycoproteomics
2006 StandoutNobel
Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity
2008
Dosimetry and thyroid cancer: the individual dosage of radioiodine
2010
Optimized 124I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer
2008
HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts
2011
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Real-Time Noninvasive Imaging of Fatty Acid Uptake in Vivo
2012 StandoutNobel
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography
2011
Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology
2012 Standout
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
2006 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Chemistry in living systems
2005 StandoutNobel
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
2011
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
2014
Prospects for MEK inhibitors for treating cancer
2014
Bone metastases from differentiated thyroid carcinoma
2008
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
2006
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Imaging and cancer: A review
2008
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy
2008
Tensor Regression with Applications in Neuroimaging Data Analysis
2013 Standout
Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum
2011 Standout
Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review
2013
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
2014
The 2017 Bethesda System for Reporting Thyroid Cytopathology
2017 Standout
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell–Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy 131 I Whole-Body Scans
2012
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
2005
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
2017 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Lanthanide Luminescence for Biomedical Analyses and Imaging
2010 Standout
A Strategy for the Selective Imaging of Glycans Using Caged Metabolic Precursors
2010 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
In Situ Imaging of Metals in Cells and Tissues
2009
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
2007
Fluorescent Sensors for Measuring Metal Ions in Living Systems
2014 Standout
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.
2005
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
2015 Standout
Imaging Tri-Fusion Multimodality Reporter Gene Expression in Living Subjects
2004 StandoutNobel
Cancer treatment and survivorship statistics, 2019
2019 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Multimodality Agents for Tumor Imaging (PET, Fluorescence) and Photodynamic Therapy. A Possible “See and Treat” Approach
2005
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Imaging Cell Surface Glycans with Bioorthogonal Chemical Reporters
2007 StandoutNobel
Guidelines for the management of thyroid cancer
2014 Standout
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
2003
Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review
2005
Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline
2012 Standout
The Treatment of Differentiated Thyroid Cancer in Children: Emphasis on Surgical Approach and Radioactive Iodine Therapy
2011
TSH and Thyrotropic Agonists: Key Actors in Thyroid Homeostasis
2012
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
2005
PET/CT Imaging of Thyroid Cancer
2011
Real-Time Bioluminescence Imaging of Glycans on Live Cells
2010 StandoutNobel
Inorganic Nanoparticles for MRI Contrast Agents
2009 Standout
Construction and Validation of Improved Triple Fusion Reporter Gene Vectors for Molecular Imaging of Living Subjects
2007 StandoutNobel
Works of Arif Sheikh being referenced
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
2012
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
2020
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
2004
Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
2007
PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.
2001